STRATA Skin Sciences Confirms Non-EGC Status in 8-K Filing
Ticker: SSKN · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1051514
| Field | Detail |
|---|---|
| Company | Strata Skin Sciences, Inc. (SSKN) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, disclosure
TL;DR
**STRATA Skin Sciences is NOT an emerging growth company, meaning full SEC reporting rules apply.**
AI Summary
STRATA Skin Sciences, Inc. filed an 8-K on January 8, 2024, indicating that it is not an 'emerging growth company' as defined by the SEC. This matters to investors because emerging growth companies have fewer reporting requirements, so STRATA's status means it must adhere to full public company disclosure rules, potentially increasing transparency but also compliance costs.
Why It Matters
This filing clarifies STRATA Skin Sciences' regulatory status, confirming it operates under full public company reporting standards, which impacts transparency and compliance costs.
Risk Assessment
Risk Level: low — This filing is a routine disclosure about the company's regulatory status and does not indicate any new financial or operational risks.
Analyst Insight
Investors should understand that STRATA Skin Sciences operates under full SEC reporting requirements, which implies greater transparency but also potentially higher compliance costs compared to an emerging growth company.
Key Players & Entities
- STRATA Skin Sciences, Inc. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported and filing date
- Delaware (company) — state of incorporation for STRATA Skin Sciences, Inc.
- 000-51481 (dollar_amount) — Commission File Number
- 13-3986004 (dollar_amount) — I.R.S. Employer Identification No.
- 5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044 (company) — address of principal executive offices
- 215-619-3200 (dollar_amount) — registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by STRATA Skin Sciences, Inc.?
The primary purpose of this 8-K filing, dated January 8, 2024, is to disclose that STRATA Skin Sciences, Inc. is not an 'emerging growth company' as defined under the Securities Act of 1933 and the Securities Exchange Act of 1934.
What does it mean for STRATA Skin Sciences, Inc. to not be an 'emerging growth company'?
Not being an 'emerging growth company' means STRATA Skin Sciences, Inc. must comply with all standard public company reporting requirements, rather than benefiting from the scaled-down disclosure rules available to emerging growth companies.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024, which is also the date of the report.
What is the business address and phone number of STRATA Skin Sciences, Inc. as stated in the filing?
The business address of STRATA Skin Sciences, Inc. is 5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044, and its telephone number is 215-619-3200.
Under which SEC Acts is the 'emerging growth company' status defined?
The 'emerging growth company' status is defined under Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) and Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-01-08 16:02:04
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SSKN The NASDAQ
Filing Documents
- ef20018284_8k.htm (8-K) — 29KB
- ef20018284_ex99-1.htm (EX-99.1) — 12KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-24-001339.txt ( ) — 188KB
- sskn-20240108.xsd (EX-101.SCH) — 4KB
- sskn-20240108_lab.xml (EX-101.LAB) — 22KB
- sskn-20240108_pre.xml (EX-101.PRE) — 16KB
- ef20018284_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure. On January 8, 2024, STRATA Skin Sciences, Inc. (the "Company") issued a press release announcing that the Company will be presenting a poster titled "Pulsed Broadband Light with Vacuum Suction (Photopneumatic Therapy) and Needle Insert to Treat Acne" at the Maui Derm 2024 Meeting to be held at the Grand Wailea in Maui, Hawaii from January 22-26, 2024.. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following press release is furnished as an exhibit to this Current Report on Form 8-K and shall not be deemed to be "filed": Exhibit No. Exhibit Description 99.1 Press release dated January 8, 2024, issued by Strata Skin Sciences, Inc. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Date: January 8, 2024 By: /s/ Christopher Lesovitz Christopher Lesovitz Chief Financial Officer